Plaque psoriasis clinical trials

Mar 23, 2026

Summary Johnson & Johnson and Protagonist Therapeutics received U.S. FDA approval for ICOTYDE (icotrokinra), the first targeted oral IL-23 receptor peptide therapy for moderate-to-severe plaque psoriasis in adults and adolescents (12+ years, ≥40 kg). Once-daily 200 mg oral tablet blocks IL-23 signaling w...

Sep 30, 2025

Regeneron’s EVKEEZA Wins FDA Approval for HoFH in Children as Young as 1 Year Regeneron Pharmaceuticals, Inc. announced that the FDA has approved EVKEEZA (evinacumab-dgnb) ANGPTL3 antibody, for children aged 1 to under 5 years with homozygous familial hypercholesterolemia (HoFH). This expands the indication from...

Apr 19, 2024

Psoriasis is one of the most frequent chronic inflammatory dermatoses in the world, with variable prevalence globally. Important factors in the variation of the prevalence of psoriasis include age, gender, geography, and ethnicity, probably due to genetic and environmental factors. Higher prevalence rates have been...

Apr 07, 2023

Psoriasis is a common skin condition that accelerates the life cycle of skin cells. More than 3% of the adult population in the United States suffers from psoriasis. That equates to more than 7.5 million US adults. According to the World Psoriasis Day Consortium, 125 million people worldwide (2-3% of the total popu...